Friday, April 24, 2026 5:22:46 PM
I’ve been thinking about my vote on Amarin and wanted to get some honest feedback from everyone here.
I originally voted NO across the board out of frustration — and I think a lot of us feel that after what this stock has done. But stepping back and looking at it more objectively, I’m starting to question whether that was the right approach.
Here’s where I’m at now:
Sarissa didn’t walk into a healthy company. They walked into a mess — legal overhang, declining revenue, broken sentiment, and a shareholder base that’s been through hell. In the last few years, they’ve at least:
* cut costs
* preserved cash (still sitting on significant reserves)
* explored partnerships/strategic options
* stabilized the business instead of letting it collapse
Has the share price improved? Obviously not. That’s the biggest failure and we all feel it.
But the question I’m asking now is:
**Do we really want to start over again?**
How many times can this company reset before it destroys whatever value is left?
Right now, Sarissa might not be perfect — but they may be the **best chance we have to actually finish something**, whether that’s a partnership, sale, or long-term strategy.
Voting NO on everything might feel justified, but does it:
* weaken the current leadership?
* create more uncertainty?
* push us into another multi-year reset?
I’m not saying they’ve earned a free pass. I’m saying I’m trying to separate frustration from what gives us the best chance going forward.
So I’m reconsidering my vote — at least on directors — because I’m not convinced blowing everything up again helps us.
Curious where everyone else stands on this. Are you sticking with NO across the board, or thinking about it differently now?
I originally voted NO across the board out of frustration — and I think a lot of us feel that after what this stock has done. But stepping back and looking at it more objectively, I’m starting to question whether that was the right approach.
Here’s where I’m at now:
Sarissa didn’t walk into a healthy company. They walked into a mess — legal overhang, declining revenue, broken sentiment, and a shareholder base that’s been through hell. In the last few years, they’ve at least:
* cut costs
* preserved cash (still sitting on significant reserves)
* explored partnerships/strategic options
* stabilized the business instead of letting it collapse
Has the share price improved? Obviously not. That’s the biggest failure and we all feel it.
But the question I’m asking now is:
**Do we really want to start over again?**
How many times can this company reset before it destroys whatever value is left?
Right now, Sarissa might not be perfect — but they may be the **best chance we have to actually finish something**, whether that’s a partnership, sale, or long-term strategy.
Voting NO on everything might feel justified, but does it:
* weaken the current leadership?
* create more uncertainty?
* push us into another multi-year reset?
I’m not saying they’ve earned a free pass. I’m saying I’m trying to separate frustration from what gives us the best chance going forward.
So I’m reconsidering my vote — at least on directors — because I’m not convinced blowing everything up again helps us.
Curious where everyone else stands on this. Are you sticking with NO across the board, or thinking about it differently now?
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
